Impact of P2Y12 Inhibitory Effects Induced by Clopidogrel on Platelet Procoagulant Activity in Type 2 Diabetes Mellitus Patients

Thrombosis Research

Volumn 124, Issue 3, 2009, Pages 318-322

  Angiolillo, Dominick J ^a   Capranzano, Piera ^a   Desai, Bhaloo ^a   Shoemaker, Steven B ^a   Charlton, Ronald ^b   Zenni, Martin M ^a   Guzman, Luis A ^a   Bass, Theodore A ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF FLORIDA HEALTH JACKSONVILLE   (United States)

Author keywords

Clopidogrel; Diabetes mellitus; Platelets; Thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; CYTOCHROME P450 3A4; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRIN; PROCOAGULANT; PURINERGIC P2Y12 RECEPTOR; THROMBIN;

ACCELERATION; ADULT; AGED; ARTICLE; BLOOD CLOTTING; CLINICAL EVALUATION; CLINICAL FEATURE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DRUG DOSE COMPARISON; DRUG MEGADOSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; POPULATION; PRIORITY JOURNAL; REACTION TIME; STEADY STATE; THROMBIN TIME; THROMBOCYTE; THROMBOELASTOGRAPHY; TREATMENT RESPONSE;

BLOOD COAGULATION FACTORS; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; MALE; MIDDLE AGED; PLATELET ACTIVATION; PLATELET AGGREGATION INHIBITORS; RECEPTORS, PURINERGIC P2; TICLOPIDINE;

EID: 67649746333     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2008.10.001     Document Type: Article

References (39)

1. Angiolillo D.J. Antiplatelet therapy in type 2 diabetes mellitus. Curr Opin Endocrinol Diabetes Obes 14 (2007) 124-131
2. Ferreira I.A., Eybrechts K.L., Mocking A.I., Kroner C., and Akkerman J.W. IRS-1 mediates inhibition of Ca2+mobilization by insulin via the inhibitory G-protein Gi. J Biol Chem 279 (2004) 3254-3264
3. Ferreira I.A., Mocking A.I., Feijge M.A., Gorter G., van Haeften T.W., Heemskerk J.W., et al. Platelet inhibition by insulin is absent in type 2 diabetes mellitus. Arterioscler Thromb Vasc Biol 26 (2006) 417-422
4. Angiolillo D.J., Fernandez-Ortiz A., Bernardo E., Ramirez C., Sabate M., Jimenez-Quevedo P., et al. Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment. Diabetes 54 (2005) 2430-2435
5. Angiolillo D.J., Bernardo E., Ramirez C., Costa M.A., Sabate M., Jimenez-Quevedo P., et al. Insulin therapy is associated with platelet dysfunction in patients with type 2 diabetes mellitus on dual oral antiplatelet treatment. J Am Coll Cardiol 48 (2006) 298-304
6. Angiolillo D.J., Shoemaker S.B., Desai B., Yuan H., Charlton R.K., Bernardo E., et al. A randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the OPTIMUS (Optimizing anti-Platelet Therapy In diabetes MellitUS) study. Circulation 115 (2007) 708-716
7. Geisler T., Anders N., Paterok M., Langer H., Stellos K., Lindemann S., et al. Platelet response to clopidogrel is attenuated in diabetic patients undergoing coronary stent implantation. Diabetes Care 30 (2007) 372-374
8. Angiolillo D.J., Bernardo E., Sabaté M., Jimenez-Quevedo P., Costa M.A., Palazuelos J., et al. Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease. J Am Coll Cardiol 50 (2007) 1541-1547
9. Fuster V., Stein B., Ambrose J.A., Badimon L., Badimon J.J., and Chesebro J.H. Atherosclerotic plaque rupture and thrombosis. Evolving concepts. Circulation 82 3 Suppl (1990) II47-II59
10. Badimon L., Meyer B.J., and Badimon J.J. Thrombin in arterial thrombosis. Haemostasis 24 (1994) 69-80
11. Gachet C., Léon C., and Hechler B. The platelet P2 receptors in arterial thrombosis. Blood Cells Mol Diseases 36 (2006) 223-227
12. Leon C., Alex M., Klocke A., Morgenstern E., Moosbauer C., Eckly A., et al. Platelet ADP receptors contribute to the initiation of intravascular coagulation. Blood 103 (2004) 594-600
13. Leon C., Ravanat C., Freund M., Cazenave J.P., and Gachet C. Differential involvement of the P2Y1 and P2Y12 receptors in platelet procoagulant activity. Arterioscler Thromb Vasc Biol 23 (2003) 1941-1947
14. Hérault J.P., Dol F., Gaich C., Bernat A., and Herbert J.M. Effect of clopidogrel on thrombin generation in platelet-rich plasma in the rat. Thromb Haemost 81 (1999) 957-960
15. van der Meijden P.E., Feijge M.A., Giesen P.L., Huijberts M., van Raak L.P., and Heemskerk J.W. Platelet P2Y12 receptors enhance signalling towards procoagulant activity and thrombin generation. A study with healthy subjects and patients at thrombotic risk. Thromb Haemost 93 (2005) 1128-1136
16. Gurbel P.A., Bliden K.P., Guyer K., Aggarwal N., and Tantry U.S. Delayed thrombin-induced platelet-fibrin clot generation by clopidogrel: a new dose-related effect demonstrated by thrombelastography in patients undergoing coronary artery stenting. Thromb Res 119 (2007) 563-570
17. Gurbel P.A., Bliden K.P., Guyer K., Cho P.W., Zaman K.A., Kreutz R.P., et al. Platelet reactivity in patients and recurrent events post-stenting: results of the PREPARE POST-STENTING Study. J Am Coll Cardiol 46 (2005) 1820-1826
18. Rivard G.E., Brummel-Ziedins K.E., Mann K.G., Fan L., Hofer A., and Cohen E. Evaluation of the profile of thrombin generation during the process of whole blood clotting as assessed by thrombelastography. J Thromb Hemost 3 (2005) 2039-2043
19. Monroe D.M., Hoffman M., and Roberts H.R. Platelets and thrombin generation. Arterioscler Thromb Vasc Biol 22 (2002) 1381-1389
20. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet 348 (1996) 1329-1339
21. Yusuf S., Zhao F., Mehta S.R., Chrolavicius S., Tognoni G., and Fox K.K. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 345 (2001) 494-502
22. Steinhubl S.R., Berger P.B., Mann III J.T., Fry E.T., DeLago A., Wilmer C., et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial (CREDO). JAMA 288 (2002) 2411-2420
23. Bhatt D.L., Flather M.D., Hacke W., Berger P.B., Black H.R., Boden W.E., et al. CHARISMA Investigators. Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. J Am Coll Cardiol 49 (2007) 1982-1988
24. Sabatine M.S., Cannon C.P., Gibson C.M., López-Sendón J.L., Montalescot G., Theroux P., et al. CLARITY-TIMI 28 Investigators. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med 352 (2005) 1179-1189
25. Chen Z.M., Jiang L.X., Chen Y.P., Xie J.X., Pan H.C., Peto R., et al. COMMIT (ClOpidogrel and Metoprolol in Myocardial Infarction Trial) collaborative group. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 366 (2005) 1607-1621
26. Di Nisio M., Bijsterveld N.R., Meijers J.C., Levi M., Büller H.R., and Peters R.J. Effects of clopidogrel on the rebound hypercoagulable state after heparin discontinuation in patients with acute coronary syndromes. J Am Coll Cardiol 46 (2005) 1582-1583
27. Ringleb P.A., Bhatt D.L., Hirsch A.T., Topol E.J., and Hacke W. Clopidogrel Versus Aspirin in Patients at Risk of Ischemic Events Investigators. Benefit of clopidogrel over aspirin is amplified in patients with a history of ischemic events. Stroke 35 (2004) 528-532
28. Bhatt D.L., Marso S.P., Hirsch A.T., Ringleb P.A., Hacke W., and Topol E.J. Amplified benefit of clopidogrel versus aspirin in patients with diabetes mellitus. Am J Cardiol 90 (2002) 625-628
29. Ho P.M., Peterson E.D., Wang L., Magid D.J., Fihn S.D., Larsen G.C., et al. Incidence of death and acute myocardial infarction associated with stopping clopidogrel after acute coronary syndrome. JAMA 299 (2008) 532-539
30. Angiolillo D.J., Fernandez-Ortiz A., Bernardo E., Ramirez C., Sabate M., Jimenez-Quevedo P., et al. Clopidogrel withdrawal is associated with proinflammatory and prothrombotic effects in patients with diabetes and coronary artery disease. Diabetes 55 (2006) 780-784
31. Angiolillo D.J., Fernandez-Ortiz A., Bernardo E., Alfonso F., Macaya C., Bass T.A., et al. Variability in individual responsiveness to clopidogrel: clinical implications, management and future perspectives. J Am Coll Cardiol 49 (2007) 1505-1516
32. Cola C., and Sabate M. Revascularization in high risk patients: diabetes mellitus. Minerva Cardioangiol 55 (2007) 557-577
33. Iakovou I., Schmidt T., Bonizzoni E., Ge L., Sangiorgi G.M., Stankovic G., et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 293 (2005) 2126-2130
34. Daemen J., Wenaweser P., Tsuchida K., Abrecht L., Vaina S., Morger C., et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet 369 (2007) 667-678
35. Urban P., Gershlick A.H., Guagliumi G., Guyon P., Lotan C., Schofer J., et al. e-Cypher Investigators. Safety of coronary sirolimus-eluting stents in daily clinical practice: one-year follow-up of the e-Cypher registry. Circulation 113 (2006) 1434-1441
36. Wiviott S.D., Braunwald E., McCabe C.H., Montalescot G., Ruzyllo W., Gottlieb S., et al. TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 357 (2007) 2001-2015
37. Wiviott S.D., Trenk D., Frelinger A.L., O'Donoghue M., Neumann F.J., Michelson A.D., et al. PRINCIPLE-TIMI 44 Investigators. Prasugrel compared with high loading-and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial. Circulation 116 (2007) 2923-2932
38. Wiviott S.D., Braunwald E., Angiolillo D.J., Meisel S., Dalby A.J., Verheugt F.W., et al. for the TRITON-TIMI 38 Investigators. Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocardial Infarction 38. Circulation 118 (2008) 1626-1636
39. Angiolillo D.J. ADP receptor antagonism: what's in the pipeline?. Am J Cardiovasc Drugs 7 (2007) 423-432